AR051349A1 - Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo. - Google Patents

Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo.

Info

Publication number
AR051349A1
AR051349A1 ARP050101155A ARP050101155A AR051349A1 AR 051349 A1 AR051349 A1 AR 051349A1 AR P050101155 A ARP050101155 A AR P050101155A AR P050101155 A ARP050101155 A AR P050101155A AR 051349 A1 AR051349 A1 AR 051349A1
Authority
AR
Argentina
Prior art keywords
alkyl
nrbrc
nrec
heterocyclyl
heteroaryl
Prior art date
Application number
ARP050101155A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406916A external-priority patent/GB0406916D0/en
Priority claimed from GB0406918A external-priority patent/GB0406918D0/en
Priority claimed from GB0423001A external-priority patent/GB0423001D0/en
Priority claimed from GB0423000A external-priority patent/GB0423000D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR051349A1 publication Critical patent/AR051349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Un compuesto de 4-carboxi pirazol que es de la formula (1) donde: A representa hidroxi; R1 representa arilo, heteroarilo unido a través de un átomo de C del anillo, o heterociclilo unido a través de un átomo de C del anillo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, halo, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, SO2RD, nitro, ciano, -CF3, -OCF3, - NRESO2RD, fenilo y heterociclilo, donde el sustituyente alquilo C1-6, a su vez, puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre cicloalquilo C5-9, halo, -NRBRC, -C(O)NRBRC, -NREC(O)RD, -SRA, -SO2RD, -ORA, oxo, fenilo, heteroarilo o heterociclilo; o R1 representa alquilo C1-6 o cicloalquilo C5-9; R2 representa fenilo sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, halo, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, - NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, -SO2RD, nitro, ciano, y heterociclilo; o R2 representa -(CH2)NHcicloalquilo C5-7 opcionalmente sustituido en el cicloalquilo con uno o más sustituyentes seleccionados entre alquilo C1-6, =CH(CH2)tH, - ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, -SO2RD, F, nitro, ciano, oxo y heterociclilo o donde dos sustituyentes pueden formar de forma conjunta un sustituyente de puente alquileno C1-2; t representa 0, 1, 2, 3, o 4, n representa 0 o 1; R3 representa heterociclilo o heteroarilo; o fenilo opcionalmente sustituido con uno o más sustituyentes seleccionado entre alquilo C1-6, halo, -ORA, -SRA, C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, - NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, -SO2RD, nitro, ciano, y heterociclilo; o R3 representa alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, - CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, SO2RD, F, nitro, ciano, oxo, fenilo, heteroarilo y heterociclilo; R4 representa H; RA representa H, -alquilo C1-6, arilalquilo, heteroarilalquilo, arilo, heterociclilo o heteroarilo; RB y RC representan independientemente H, -alquilo C1-6, arilo, heterociclilo o heteroarilo; o RB y RC junto con el átomo de N al que están unidos forman un grupo cíclico saturado de 5 o 6 miembros; RD se selecciona entre el grupo que consiste en - alquilo C1-6, arilo, heterociclilo, heteroarilo, arilalquilo y heteroarilalquilo; RE representa H o alquilo C1-6; RF y RG se seleccionan independientemente entre el grupo que consiste en H, -alquilo C1-6, arilo, heteroarilo, arilalquilo y heteroarilalquilo; o RF y RG junto con el átomo de N al que están unidos forman un grupo cíclico saturado de 5 o 6 miembros; y sales, solvatos y ésteres de los mismos. Formulacion farmacéutica que comprende al menos un compuesto de formula (1) y sales farmacéuticamente aceptables, solvatos y ésteres de los mismos, junto con al menos un diluyente o vehículo farmacéuticamente aceptable; y proceso para la preparacion de un compuesto de formula (1) mediante el tratamiento de un compuesto de formula (2) donde A es un grupo alcoxi, benciloxi o sililoxi y R1, R2, R3 y R4 son como se han definido anteriormente para la formula (1), con una base. Uso de un compuesto de formula (1) y sales farmacéuticamente aceptable, solvatos y ésteres de los mismos para la fabricacion de un medicamento para tratar o prevenir infecciones virales, mediante l administracion a un sujeto en necesidad del mismo, de una cantidad eficaz de dicho compuesto de formula (1). Preferentemente, la infeccion vírica es por VHC y el compuesto compuesto de formula (1) se administra en una forma de dosificacion oral. Reivindicacion 1: Un compuesto de 4-carboxi pirazol caracterizado porque es de la formula (1): donde A representa hidroxi; R1 representa arilo, heteroarilo unido a través de un átomo de C del anillo, o heterociclilo unido a través de un átomo de C del anillo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, halo, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, SO2RD, nitro, ciano, -CF3, -OCF3, -NRESO2RD, fenilo y heterociclilo, donde el sustituyente alquilo C1-6, a su vez, puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados entre cicloalquilo C5-9, halo, -NRBRC, -C(O)NRBRC, -NREC(O)RD, -SRA, -SO2RD, -ORA, oxo, fenilo, heteroarilo o heterociclilo; o R1 representa alquilo C1-6 o cicloalquilo C5-9; R2 representa fenilo sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, halo, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, -SO2RD, nitro, ciano, y heterociclilo; o R2 representa - (CH2)NHcicloalquilo C5-7 opcionalmente sustituido en el cicloalquilo con uno o más sustituyentes seleccionados entre alquilo C1-6, =CH(CH2)tH, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, - SO2RD, F, nitro, ciano, oxo y heterociclilo o donde dos sustituyentes pueden formar de forma conjunta un sustituyente de puente alquileno C1-2; t representa 0, 1, 2, 3, o 4, n representa 0 o 1; R3 representa heterociclilo o heteroarilo; o fenilo opcionalmente sustituido con uno o más sustituyentes seleccionado entre alquilo C1-6, halo, -ORA, -SRA, C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, -SO2RD, nitro, ciano, y heterociclilo; o R3 representa alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1-6, -ORA, -SRA, -C(O)NRBRC, -C(O)RD, -CO2H, -CO2RD, -NRBRC, -NREC(O)RD, -NRECO2RD, -NREC(O)NRFRG, -SO2NRFRG, SO2RD, F, nitro, ciano, oxo, fenilo, heteroarilo y heterociclilo; R4 representa H; RA representa H, -alquilo C1-6, arilalquilo, heteroarilalquilo, arilo, heterociclilo o heteroarilo; RB y RC representan independientemente H, -alquilo C1-6, arilo, heterociclilo o heteroarilo; o RB y RC junto con el átomo de N al que están unidos forman un grupo cíclico saturado de 5 o 6 miembros; RD se selecciona entre el grupo que consiste en -alquilo C1-6, arilo, heterociclilo, heteroarilo, arilalquilo y heteroarilalquilo; RE representa H o alquilo C1-6; RF y RG se seleccionan independientemente entre el grupo que consiste en H, -alquilo C1-6, arilo, heteroarilo, arilalquilo y heteroarilalquilo; o RF y RG junto con el átomo de N al que están unidos forman un grupo cíclico saturado de 5 o 6 miembros; y sales, solvatos y ésteres de los mismos.
ARP050101155A 2004-03-26 2005-03-23 Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo. AR051349A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0406916A GB0406916D0 (en) 2004-03-26 2004-03-26 Compounds
GB0406918A GB0406918D0 (en) 2004-03-26 2004-03-26 Compounds
GB0423001A GB0423001D0 (en) 2004-10-15 2004-10-15 Compounds
GB0423000A GB0423000D0 (en) 2004-10-15 2004-10-15 Compounds

Publications (1)

Publication Number Publication Date
AR051349A1 true AR051349A1 (es) 2007-01-10

Family

ID=34962958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101155A AR051349A1 (es) 2004-03-26 2005-03-23 Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo.

Country Status (10)

Country Link
US (1) US20070167507A1 (es)
EP (1) EP1730116B1 (es)
JP (1) JP2007530516A (es)
AR (1) AR051349A1 (es)
AT (1) ATE372323T1 (es)
DE (1) DE602005002357T2 (es)
ES (1) ES2292126T3 (es)
PE (1) PE20060250A1 (es)
TW (1) TW200602044A (es)
WO (1) WO2005092863A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050034A1 (en) * 2004-10-29 2006-05-11 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
JP4663733B2 (ja) * 2004-10-29 2011-04-06 シェーリング コーポレイション 抗ウイルス物質としての置換５−オキソピラゾールおよび置換［１，２，４］トリアゾール
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
WO2007147794A1 (en) * 2006-06-19 2007-12-27 Smithkline Beecham Corporation Furan derivatives and their use as antiviral agents
CA2670260A1 (en) * 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
EP2086966B1 (en) * 2006-11-17 2011-09-14 GlaxoSmithKline LLC 2-carboxy thiophene derivatives as anti viral agents
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
EP2331522B1 (en) * 2008-08-01 2013-09-18 Purdue Pharma LP Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2010118159A1 (en) * 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2014053450A1 (de) 2012-10-02 2014-04-10 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE370137T1 (de) * 2001-11-02 2007-09-15 Glaxo Group Ltd 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
US20050009873A1 (en) * 2001-11-02 2005-01-13 Gianpaolo Bravi Acyl dihydro pyrrole derivatives as hcv inhibitors
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
WO2004096210A1 (en) * 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors

Also Published As

Publication number Publication date
DE602005002357D1 (de) 2007-10-18
US20070167507A1 (en) 2007-07-19
ES2292126T3 (es) 2008-03-01
ATE372323T1 (de) 2007-09-15
EP1730116A1 (en) 2006-12-13
DE602005002357T2 (de) 2008-05-29
WO2005092863A1 (en) 2005-10-06
PE20060250A1 (es) 2006-04-02
EP1730116B1 (en) 2007-09-05
TW200602044A (en) 2006-01-16
JP2007530516A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
AR051349A1 (es) Compuestos de 4-carboxi pirazol, formulacion farmaceutica que los comprende y procesos de preparacion del mismo.
AR037182A1 (es) Compuestos del acido 4,5-disubstituido-n-acilpirrolidina-2-carboxilico, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y proceso para su fabricacion
JP2016522172A5 (es)
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR057131A1 (es) Derivados de purina como inmunomodulador
AR061629A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
AR037181A1 (es) Compuesto de 4-heteroaril-(5-miembros) acil pirrolidina, formulacion farmaceutica que lo comprende, uso del mismo para preparar un medicamento y procedimiento para su preparacion
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR116474A1 (es) DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
AR062270A1 (es) Compuestos de heteroarilo inhibidores de enzimas de activacion e1, composiciones farmaceuticas que los contienen y usos en desordenes asociados a proliferacion celular,tales como canceres y trastornos inflamatorios.
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR058362A1 (es) Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos
AR038823A1 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c
JP2011079828A5 (es)
AR048607A1 (es) Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos
AR035933A1 (es) Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato.
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal